Levacetylleucine: Revision history

10 April 2025

• curprev 06:2406:24, 10 April 2025 Parth Vikram Singh talk contribs 22,144 bytes +21 No edit summary
• curprev 02:0602:06, 10 April 2025 Parth Vikram Singh talk contribs 22,123 bytes +1,093 No edit summary
• curprev 02:0402:04, 10 April 2025 Parth Vikram Singh talk contribs 21,030 bytes +56 No edit summary
• curprev 02:0002:00, 10 April 2025 Parth Vikram Singh talk contribs 20,974 bytes +7 No edit summary
• curprev 01:5501:55, 10 April 2025 Parth Vikram Singh talk contribs 20,967 bytes +132 No edit summary

9 April 2025

• curprev 17:4217:42, 9 April 2025 Parth Vikram Singh talk contribs 20,835 bytes +1 No edit summary
• curprev 17:3217:32, 9 April 2025 Parth Vikram Singh talk contribs 20,834 bytes 0 No edit summary
• curprev 17:2017:20, 9 April 2025 Parth Vikram Singh talk contribs 20,834 bytes +3,734 No edit summary
• curprev 16:4216:42, 9 April 2025 Parth Vikram Singh talk contribs 17,100 bytes −13 No edit summary
• curprev 16:3916:39, 9 April 2025 Parth Vikram Singh talk contribs 17,113 bytes +2,575 No edit summary
• curprev 16:3016:30, 9 April 2025 Parth Vikram Singh talk contribs 14,538 bytes +341 No edit summary
• curprev 16:2816:28, 9 April 2025 Parth Vikram Singh talk contribs 14,197 bytes +2,287 No edit summary
• curprev 11:4411:44, 9 April 2025 Parth Vikram Singh talk contribs 11,910 bytes −9 No edit summary
• curprev 11:4311:43, 9 April 2025 Parth Vikram Singh talk contribs 11,919 bytes +10 No edit summary
• curprev 11:2911:29, 9 April 2025 Parth Vikram Singh talk contribs 11,909 bytes −2 No edit summary
• curprev 11:1911:19, 9 April 2025 Parth Vikram Singh talk contribs 11,911 bytes +954 No edit summary
• curprev 11:0711:07, 9 April 2025 Parth Vikram Singh talk contribs 10,957 bytes +1,246 No edit summary
• curprev 11:0311:03, 9 April 2025 Parth Vikram Singh talk contribs 9,711 bytes +1 No edit summary
• curprev 11:0111:01, 9 April 2025 Parth Vikram Singh talk contribs 9,710 bytes −2 No edit summary
• curprev 10:5910:59, 9 April 2025 Parth Vikram Singh talk contribs 9,712 bytes +2,828 No edit summary
• curprev 10:5510:55, 9 April 2025 Parth Vikram Singh talk contribs 6,884 bytes +646 No edit summary
• curprev 10:4710:47, 9 April 2025 Parth Vikram Singh talk contribs 6,238 bytes +6 No edit summary
• curprev 10:4410:44, 9 April 2025 Parth Vikram Singh talk contribs 6,232 bytes −1 No edit summary
• curprev 10:4110:41, 9 April 2025 Parth Vikram Singh talk contribs 6,233 bytes +1 No edit summary
• curprev 10:3210:32, 9 April 2025 Parth Vikram Singh talk contribs 6,232 bytes +1,326 No edit summary
• curprev 10:2010:20, 9 April 2025 Parth Vikram Singh talk contribs 4,906 bytes +1,089 No edit summary
• curprev 10:0610:06, 9 April 2025 Parth Vikram Singh talk contribs 3,817 bytes +4 No edit summary
• curprev 10:0310:03, 9 April 2025 Parth Vikram Singh talk contribs 3,813 bytes −1 No edit summary
• curprev 10:0110:01, 9 April 2025 Parth Vikram Singh talk contribs 3,814 bytes −4 No edit summary
• curprev 09:5809:58, 9 April 2025 Parth Vikram Singh talk contribs 3,818 bytes +3 No edit summary
• curprev 09:5609:56, 9 April 2025 Parth Vikram Singh talk contribs 3,815 bytes −2 No edit summary
• curprev 09:5409:54, 9 April 2025 Parth Vikram Singh talk contribs 3,817 bytes −3 No edit summary
• curprev 09:5109:51, 9 April 2025 Parth Vikram Singh talk contribs 3,820 bytes −1 No edit summary
• curprev 09:4809:48, 9 April 2025 Parth Vikram Singh talk contribs 3,821 bytes −266 No edit summary
• curprev 09:4409:44, 9 April 2025 Parth Vikram Singh talk contribs 4,087 bytes +2,579 No edit summary
• curprev 08:4508:45, 9 April 2025 Parth Vikram Singh talk contribs 1,508 bytes −24 No edit summary

8 April 2025

• curprev 09:5609:56, 8 April 2025 Parth Vikram Singh talk contribs 1,532 bytes +1,532 Created page with "{{DrugProjectFormSinglePage |authorTag={{PVS}} |genericName=levacetylleucine |indicationType=treatment |indication=AQNEURSA is FDA approved for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (incidence ≥5% and greater than placebo) are abdominal pain, dysphagia, upper respiratory tract infections, and vomiting. |..."